CAS 145599-86-6 | 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- | CAS Number 145599-86-6

Title	Journal
Plasma 2-hydroxyglutarate and hexanoylcarnitine levels are potential biomarkers for skeletal muscle toxicity in male Fischer 344 rats.	The Journal of toxicological sciences 20170101
Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin.	Toxicology and applied pharmacology 20160901
The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.	Drug metabolism and disposition: the biological fate of chemicals 20160501
Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins.	Joint, bone, spine : revue du rhumatisme 20140101
Turning up the pressure on vascular disease.	Current neurovascular research 20140101
Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120701
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.	Journal of medicinal chemistry 20120524
Effects of cerivastatin on adrenergic pathways, hypertrophic growth and TGFbeta expression in adult ventricular cardiomyocytes.	European journal of cell biology 20120501
A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.	Clinical pharmacology and therapeutics 20120501
The need for translational research on drug-drug interactions.	Clinical pharmacology and therapeutics 20120501
Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.	Epidemiology (Cambridge, Mass.) 20120301
[Effects of acidification and alkalinization agents on statins-induced muscle toxicity].	Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).	PLoS computational biology 20111201
Biological perspectives: update on newer antipsychotic drugs: are they evidence based?	Perspectives in psychiatric care 20111001
Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats.	The Journal of toxicological sciences 20110801
Cerivastatin, genetic variants, and the risk of rhabdomyolysis.	Pharmacogenetics and genomics 20110501
Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling.	Analytical biochemistry 20110301
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.	Drug metabolism and disposition: the biological fate of chemicals 20110201
A predictive ligand-based Bayesian model for human drug-induced liver injury.	Drug metabolism and disposition: the biological fate of chemicals 20101201
Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.	Diabetes & vascular disease research 20101001
Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.	Pharmacogenetics and genomics 20101001
Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels.	Journal of neurochemistry 20100901
Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.	International journal of clinical practice 20100501
Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries.	EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100501
Quantitative phenotyping via deep barcode sequencing.	Genome research 20091001
Cocaine-induced coronary artery dissection.	JACC. Cardiovascular interventions 20091001
Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.	British journal of clinical pharmacology 20090901
[Metabolic rhabdomyolysis during statin therapy].	La Revue de medecine interne 20090801
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.	British journal of pharmacology 20090801
Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways.	Molecular pharmacology 20090601
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.	The Journal of pharmacy and pharmacology 20090601
Effect of a combined therapeutic approach of intensive lipid management, omega-3 fatty acid supplementation, and increased serum 25 (OH) vitamin D on coronary calcium scores in asymptomatic adults.	American journal of therapeutics 20090101
Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy.	Xenobiotica; the fate of foreign compounds in biological systems 20090101
The social costs of dangerous products: an empirical investigation.	Cornell journal of law and public policy 20090101
Dermatomyositis induced by drug therapy: a review of case reports.	Journal of the American Academy of Dermatology 20081101
[Anticoagulation in atrial fibrillation].	Hamostaseologie 20081001
Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.	International journal of cancer 20080901
Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.	Clinical pharmacology and therapeutics 20080801
Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes.	Drug metabolism and disposition: the biological fate of chemicals 20080701
Effects of cerivastatin withdrawal on statin persistence.	The Annals of pharmacotherapy 20080701
Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells.	International journal of cardiology 20080623
Severe obstructive sleep apnea after cerivastatin therapy: a case report.	Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20080615
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.	Journal of medicinal chemistry 20080508
Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model.	Circulation journal : official journal of the Japanese Circulation Society 20080501
3-Hydroxy-3-methylglutaryl coenzyme A reductase in rainbow trout: effects of fasting and statin drugs on activities and mRNA transcripts.	Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20080401
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.	Pharmacogenetics and genomics 20080401
Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance.	Surgical infections 20080401
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.	Pharmacoepidemiology and drug safety 20080301
Metabolic myopathies discovered during investigations of statin myopathy.	The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080301
Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.	International journal of cardiology 20080227
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.	Bioorganic & medicinal chemistry letters 20080201
Statins attenuate polymethylmethacrylate-mediated monocyte activation.	Acta orthopaedica 20080201
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.	Journal of medicinal chemistry 20080110
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?	Advances in cardiology 20080101
Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.	Internal medicine (Tokyo, Japan) 20080101
Early detection of adverse drug events within population-based health networks: application of sequential testing methods.	Pharmacoepidemiology and drug safety 20071201
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.	Oncology reports 20071101
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.	Calcified tissue international 20071101
Physiogenomic association of statin-related myalgia to serotonin receptors.	Muscle & nerve 20070901
Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.	Clinical and experimental pharmacology & physiology 20070901
Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.	Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20070901
Preventive effects of bicarbonate on cerivastatin-induced apoptosis.	International journal of pharmaceutics 20070816
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.	Bioorganic & medicinal chemistry 20070815
Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.	Toxicology and applied pharmacology 20070815
[Rhabdomyolysis induced by statins].	Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810
Effect of cerivastatin on peripheral capillary permeability to albumin and peripheral nerve function in diabetic rats.	Diabetes & metabolism 20070601
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070601
Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070401
Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.	Pharmacological research 20070401
Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.	Current opinion in lipidology 20070401
Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages.	The American journal of pathology 20070401
Subcutaneous administration of lactone form of simvastatin stimulates ectopic osteoinduction by rhBMP-2.	Oral diseases 20070301
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.	Lipids 20070301
Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells.	Atherosclerosis 20070101
Molecular basis of differences among statins and a comparison with antioxidant vitamins.	The American journal of cardiology 20061204
RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation.	Cell death and differentiation 20061101
Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.	Metabolism: clinical and experimental 20061101
Formulary committees and Medicare Part D.	Journal of the American Geriatrics Society 20061101
Toxicity of statins on rat skeletal muscle mitochondria.	Cellular and molecular life sciences : CMLS 20061001
Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study.	Heart and vessels 20060901
Inhibitory effects of statins on human monocarboxylate transporter 4.	International journal of pharmaceutics 20060706
Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.	Experimental biology and medicine (Maywood, N.J.) 20060601
Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.	Circulation 20060509
Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.	Journal of cardiovascular pharmacology 20060501
Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells.	Atherosclerosis 20060401
Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells.	Allergy 20060301
Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.	Journal of the American Geriatrics Society 20060301
'Anti-inflammatory' drugs and their effects on type 2 diabetes.	Diabetes technology & therapeutics 20060201
Statins and osteoporosis: new role for old drugs.	The Journal of pharmacy and pharmacology 20060101
Cerivastatin and hypercholesterolemia reduce apoptosis of cardiomyocytes in guinea pig papillary muscle subjected to hypoxia/reoxygenation.	Pharmacological reports : PR 20060101
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.	Cardiovascular diabetology 20060101
Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.	Cardiovascular research 20051201
Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.	Cardiovascular research 20051201
Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.	Toxicological sciences : an official journal of the Society of Toxicology 20051201
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.	Diabetic medicine : a journal of the British Diabetic Association 20051201
Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.	Diabetic medicine : a journal of the British Diabetic Association 20051201
The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.	The Journal of surgical research 20051101
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.	The Journal of pharmacy and pharmacology 20051101
Differential associations of statin and fibrate treatment with carotid arterial remodeling.	American journal of hypertension 20051101
Statin toxicity: a situation that mimics viral hepatitis.	International journal of clinical pharmacology and therapeutics 20051101
[Drug combinations: statins and fibrates].	Arquivos brasileiros de cardiologia 20051001
Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.	Journal of pharmaceutical and biomedical analysis 20050915
Binding thermodynamics of statins to HMG-CoA reductase.	Biochemistry 20050906
Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.	The Journal of pharmacology and experimental therapeutics 20050901
Differences between statins on clinical endpoints: a population-based cohort study.	Current medical research and opinion 20050901
Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs.	Harvard heart letter : from Harvard Medical School 20050901
New light on statin side effects. What recent research on the cholesterol drugs means to you.	Heart advisor 20050801
[High doses statins administration causing rhabdomyolysis: case report].	Arquivos brasileiros de endocrinologia e metabologia 20050801
Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor.	Drug metabolism and disposition: the biological fate of chemicals 20050701
Combination therapy with cerivastatin and nifedipine improves endothelial dysfunction after balloon injury in porcine coronary arteries.	Journal of cardiovascular pharmacology 20050701
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B15, SLCO1B115 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.	Pharmacogenetics and genomics 20050701
The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.	Diabetes care 20050701
No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease.	Diabetes care 20050701
In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.	European journal of endocrinology 20050701
The issue of statin safety: where do we stand?	Circulation 20050614
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.	Circulation 20050614
Prediction of genotoxicity of chemical compounds by statistical learning methods.	Chemical research in toxicology 20050601
Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20050601
Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.	Diabetes, obesity & metabolism 20050501
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al.	Diabetes care 20050501
More on: fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells.	Journal of thrombosis and haemostasis : JTH 20050501
Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.	Journal of clinical pharmacy and therapeutics 20050401
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.	American heart journal 20050301
Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study.	International journal of cardiology 20050227
Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway.	The Journal of biological chemistry 20050225
Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.	Life sciences 20050225
Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).	Bioorganic & medicinal chemistry letters 20050215
Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.	Molecular therapy : the journal of the American Society of Gene Therapy 20050201
Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.	Heart and vessels 20050201
Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.	Current medical research and opinion 20050201
Differential effect of cerivastatin and L-arginine on the vascular function of human radial and left internal thoracic arteries.	Journal of cardiac surgery 20050101
Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.	Toxicologic pathology 20050101
Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.	Journal of atherosclerosis and thrombosis 20050101
Mechanisms of calcium release from the sarcoplasmic reticulum in skeletal muscle.	Advances in experimental medicine and biology 20050101
[Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].	Therapie 20050101
[Comparison of reports from patients and health professionals: statins and muscle disorders].	Therapie 20050101
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.	American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101
Acute effect of cerivastatin on cardiac regional ischemia in a rat model mimicking off-pump coronary surgery.	Journal of cardiac surgery 20050101
[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].	Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences 20050101
In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats.	Drug metabolism and disposition: the biological fate of chemicals 20041201
Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.	Diabetes care 20041201
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.	JAMA 20041201
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.	JAMA 20041201
Bayer's response to 'potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis'.	JAMA 20041201
The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.	American journal of hypertension 20041201
Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.	Journal of cellular biochemistry 20041115
Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies.	Journal of pharmaceutical and biomedical analysis 20041115
Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.	Expert opinion on drug safety 20041101
Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.	Thrombosis and haemostasis 20041101
The effect of cerivastatin therapy on vascular responses to endothelin antagonists in humans.	Journal of cardiovascular pharmacology 20041101
Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.	Circulation 20041012
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.	The Journal of pharmacology and experimental therapeutics 20041001
Simvastatin and survival in sepsis.	Circulation 20040921
Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.	European journal of pharmacology 20040913
Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.	The Journal of biological chemistry 20040910
Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.	Applied immunohistochemistry & molecular morphology : AIMM 20040901
Bayer to settle lawsuits over Baycol.	Health news (Waltham, Mass.) 20040901
Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse.	Circulation 20040831
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.	Arteriosclerosis, thrombosis, and vascular biology 20040801
The cerivastatin withdrawal crisis: a 'post-mortem' analysis.	Health policy (Amsterdam, Netherlands) 20040801
Combined antihypertensive and lipid-lowering treatment.	Current hypertension reports 20040801
Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.	Circulation journal : official journal of the Japanese Circulation Society 20040801
Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.	Naunyn-Schmiedeberg's archives of pharmacology 20040801
Effect of cerivastatin on endothelial dysfunction and aortic CD36 expression in diabetic hyperlipidemic rats.	Hypertension research : official journal of the Japanese Society of Hypertension 20040801
Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.	Circulation 20040727
Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis.	Arteriosclerosis, thrombosis, and vascular biology 20040701
Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis.	Hypertension (Dallas, Tex. : 1979) 20040601
Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.	International journal of oncology 20040501
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.	Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040501
Cerivastatin activates endothelial calcium-activated potassium channels and thereby modulates endothelial nitric oxide production and cell proliferation.	Journal of the American Society of Nephrology : JASN 20040401
Cerivastatin-induced polymyalgia rheumatica-like illness.	Clinical rheumatology 20040401
[Polymyositis induced or associated with lipid-lowering drugs: five cases].	La Revue de medecine interne 20040401
Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.	International journal of cardiology 20040301
Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats.	Bone 20040301
Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide.	European journal of pharmacology 20040206
Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.	European journal of clinical pharmacology 20040201
Beneficial effects of statins in patients with non-ischemic heart failure.	Zeitschrift fur Kardiologie 20040201
Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.	Drug safety 20040101
Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.	Toxicology and applied pharmacology 20040101
Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases.	Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20040101
The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells.	BMC cardiovascular disorders 20040101
Cerivastatin does not prevent oxidative injury of human aortic endothelial cells.	Texas Heart Institute journal 20040101
A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.	Journal of human genetics 20040101
Differential in vitro response of the human radial artery versus left internal thoracic artery to cerivastatin: implications to bypass grafting.	The Annals of thoracic surgery 20031201
Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development.	Circulation research 20031114
HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.	Basic research in cardiology 20031101
Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.	International journal of clinical pharmacology and therapeutics 20031101
Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers.	Journal of pharmacological sciences 20031101
Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine.	The Journal of biological chemistry 20031031
Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins.	Circulation 20031028
Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells.	Arteriosclerosis, thrombosis, and vascular biology 20031001
Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats.	Transplantation 20030915
Cardiac magnetic resonance imaging in small animal models of human heart failure.	Medical image analysis 20030901
Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.	International journal of cardiology 20030901
Platelet hyperactivity after statin treatment discontinuation.	Thrombosis and haemostasis 20030901
The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.	Journal of cardiovascular pharmacology 20030901
Second hand smoke stimulates tumor angiogenesis and growth.	Cancer cell 20030901
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.	Journal of molecular and cellular cardiology 20030801
Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.	Clinical pharmacology and therapeutics 20030801
Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.	British journal of clinical pharmacology 20030801
HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.	Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030801
Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.	Circulation 20030722
Intestinal pseudobstruction as presenting event of fatal cerivastatin-induced myopathy.	Journal of neurology 20030701
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.	Molecular and cellular biochemistry 20030701
Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins.	Journal of the National Cancer Institute 20030618
Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.	The American journal of cardiology 20030615
Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model.	Diabetologia 20030601
Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.	Arteriosclerosis, thrombosis, and vascular biology 20030501
Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.	Expert opinion on drug safety 20030501
Vascular smooth muscle cell activation by C-reactive protein.	Cardiovascular research 20030401
The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction.	Molecular and cellular biochemistry 20030401
Safety and statin therapy: reconsidering the risks and benefits.	Archives of internal medicine 20030324
Bayer is forced to release documents over withdrawal of cerivastatin.	BMJ (Clinical research ed.) 20030308
How a statin might destroy a drug company.	Lancet (London, England) 20030308
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.	Cellular signalling 20030301
Statins and myotoxicity.	Current atherosclerosis reports 20030301
Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels.	Journal of cardiovascular pharmacology 20030301
Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.	Thrombosis and haemostasis 20030301
Statins and myotoxicity.	Trends in pharmacological sciences 20030301
Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression.	Biochimica et biophysica acta 20030217
HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway.	Atherosclerosis 20030201
Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.	The Journal of pharmacology and experimental therapeutics 20030201
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030201
HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells.	Arteriosclerosis, thrombosis, and vascular biology 20030201
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].	Der Nervenarzt 20030201
[Cerivastatin and the PRINCESS study: reflexions after 1 year].	Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20030201
Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).	Circulation 20030128
Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil.	Neurology 20030114
Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.	American journal of nephrology 20030101
Effects of cerivastatin on vascularized allogenic bone transplantation in rats treated with cyclosporine A.	Calcified tissue international 20030101
Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA.	Kidney international 20030101
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.	Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030101
HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.	Stroke 20030101
Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.	Journal of leukocyte biology 20030101
Issues that led to the withdrawal of cerivastatin.	Current atherosclerosis reports 20030101
Cerivastatin: a cellular and molecular drug for the future?	Cellular and molecular life sciences : CMLS 20030101
[Information regarding adverse drug effects and treatment indications ('package inserts') exemplified by cervistatin (Lipobay)].	Wiener medizinische Wochenschrift (1946) 20030101
Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells.	Journal of atherosclerosis and thrombosis 20030101
[Adverse effects of statins].	Therapie 20030101
[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].	Wiener medizinische Wochenschrift (1946) 20030101
Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation.	Journal of diabetes and its complications 20030101
Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.	Preventive cardiology 20030101
Interaction between fibrates and statins--metabolic interactions with gemfibrozil.	Drug metabolism and drug interactions 20030101
Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.	BMC family practice 20030101
Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.	Circulation 20021203
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.	Drug metabolism and disposition: the biological fate of chemicals 20021201
Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina.	Archives of ophthalmology (Chicago, Ill. : 1960) 20021201
Limited adherence to safety instructions in drug leaflets.	British journal of clinical pharmacology 20021201
Gemfibrozil greatly increases plasma concentrations of cerivastatin.	Clinical pharmacology and therapeutics 20021201
Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.	Japanese journal of pharmacology 20021201
High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.	Pharmacoepidemiology and drug safety 20021201
Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.	Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20021201
Side effects of statins--prevalence, relevance, consequences.	Wiener klinische Wochenschrift 20021130
Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).	Cancer letters 20021128
Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.	FEBS letters 20021120
Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.	Journal of the American College of Cardiology 20021106
Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells.	Atherosclerosis 20021101
Dysbetalipoproteinaemia--clinical and pathophysiological features.	South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20021101
Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin.	European journal of pharmacology 20021025
TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS.	Cardiovascular research 20021001
Anti-inflammatory effect of cerivastatin in vascular injury independent of serum cholesterol and blood pressure lowering effects in mouse model.	Chinese journal of traumatology = Zhonghua chuang shang za zhi 20021001
Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia.	The American journal of cardiology 20021001
Rhabdomyolysis and cerivastatin: was it a problem of dose?	CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021001
Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.	British journal of clinical pharmacology 20021001
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.	International journal of hematology 20021001
[Surrogate end points as a clinical and public health problem. The cerivastatin case].	Medicina clinica 20020907
Postischemic acute renal failure is reduced by short-term statin treatment in a rat model.	Journal of the American Society of Nephrology : JASN 20020901
Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis.	The American journal of forensic medicine and pathology 20020901
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.	Stroke 20020901
Controversy surrounding the safety of cerivastatin.	Expert opinion on drug safety 20020901
Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation.	Circulation 20020827
ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.	Circulation 20020820
Contacting patients of a Pakistani hospital about a drug recall.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020815
ACC/AHA/NHLBI clinical advisory on the use and safety of statins.	Journal of the American College of Cardiology 20020807
Mechanisms of inhibitory effects of cerivastatin on rat vascular smooth muscle cell growth.	Journal of cardiovascular pharmacology 20020801
Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.	Diabetes 20020801
The use of statins after solid organ transplantation.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020801
Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice.	Circulation research 20020726
Severe rhabdomyolysis related to cerivastatin without gemfibrozil.	Annals of internal medicine 20020702
Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes.	Atherosclerosis 20020701
Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine.	Clinical chemistry 20020701
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.	Journal of vascular surgery 20020701
Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats.	Bone 20020701
Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.	Pharmacology & therapeutics 20020701
Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol.	Bulletin of experimental biology and medicine 20020701
Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.	Biochimica et biophysica acta 20020612
Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells.	Cardiovascular research 20020601
Cerivastatin and the dissemination of adverse event information.	The Annals of pharmacotherapy 20020601
Rhabdomyolysis from high-dose cerivastatin therapy.	The Annals of pharmacotherapy 20020601
Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020601
Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.	Pharmacotherapy 20020601
Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.	Arteriosclerosis, thrombosis, and vascular biology 20020601
Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function.	Arteriosclerosis, thrombosis, and vascular biology 20020601
Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries.	The Annals of thoracic surgery 20020601
A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia.	Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 20020601
[Rhabdomyolisis associated with cerivastatin and cyclosporine combination therapy].	Medicina clinica 20020518
[Acute cholestatic hepatitis induced by cerivastatin].	Medicina clinica 20020518
Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.	Drug metabolism and disposition: the biological fate of chemicals 20020501
Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020501
Statins and the assessment of endothelial function.	Journal of internal medicine 20020501
Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.	Lipids 20020501
Statins and muscles: what price glory?	Joint, bone, spine : revue du rhumatisme 20020501
Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.	Current hypertension reports 20020401
HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.	The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20020401
Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy.	The Annals of pharmacotherapy 20020401
Cerivastatin-induced rhabdomyolysis: 11 case reports.	Pharmacotherapy 20020401
Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.	Arteriosclerosis, thrombosis, and vascular biology 20020401
[Myotoxicity and rhabdomyolisis due to statins].	Nederlands tijdschrift voor geneeskunde 20020302
Statin stories.	Diabetes, obesity & metabolism 20020301
Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.	The British journal of general practice : the journal of the Royal College of General Practitioners 20020301
HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.	Cardiovascular drugs and therapy 20020301
Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.	Circulation 20020226
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.	The American journal of cardiology 20020215
Cerivastatin and reports of fatal rhabdomyolysis.	The New England journal of medicine 20020214
Statins have biphasic effects on angiogenesis.	Circulation 20020212
Why some patients respond poorly to statins and how this might be remedied.	European heart journal 20020201
Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case--a modern Pandora's box.	Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20020201
Risperidone and severe cerivastatin-induced rhabdomyolysis.	Journal of internal medicine 20020201
Apolipoprotein E alleles, dyslipemia and kidney transplantation.	Transplantation proceedings 20020201
Effects of cerivastatin in dyslipemia and other cardiovascular risk factors after renal transplantation.	Transplantation proceedings 20020201
Cholesterol drugs: very safe and highly beneficial.	The Johns Hopkins medical letter health after 50 20020201
Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.	Circulation 20020129
Cerivastatin and endothelial function in elderly patients with diabetes mellitus.	Circulation 20020129
Bayer faces Swiss criminal probe over cerivastatin.	BMJ (Clinical research ed.) 20020119
Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase.	FEBS letters 20020116
Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.	Biochemical and biophysical research communications 20020111
Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.	Journal of internal medicine 20020101
[Unexpected consequences of an expected adverse effect of cerivastatine].	La Revue de medecine interne 20020101
[Attitude to and marketing of cerivastatin].	Acta medica Austriaca 20020101
[Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].	Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20020101
Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat.	Polish journal of pharmacology 20020101
[Myopathy due to statins, a dose-dependent effect, and of what kind?].	Atencion primaria 20020101
Cerivastatin induces rhabdomyolysis and acute renal failure.	Nephron 20020101
HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.	Internal medicine journal 20020101
Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.	WMJ : official publication of the State Medical Society of Wisconsin 20020101
A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients.	BMC nephrology 20020101
[Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].	Lijecnicki vjesnik 20020101
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.	Biochemical and biophysical research communications 20011214
[Myotoxicity and rhabdomyolisis due to statins].	Nederlands tijdschrift voor geneeskunde 20011208
Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20011201
Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.	Arteriosclerosis, thrombosis, and vascular biology 20011201
Top ten health stories of 2001.	Harvard health letter 20011201
The withdrawal of Baycol (cerivastatin).	Adverse drug reactions and toxicological reviews 20011201
[Rhabdomyolysis associated with combined treatment of cerivastatin and gemfibrozil].	Revista clinica espanola 20011201
Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.	Nutrition, metabolism, and cardiovascular diseases : NMCD 20011201
Other reports of cerivastatin-induced rhabdomyolysis.	Archives of internal medicine 20011126
Another report of acute rhabdomyolysis following cerivastatin monotherapy.	Archives of internal medicine 20011126
Case reports of rhabdomyolysis associated with cerivastatin therapy.	Archives of internal medicine 20011126
Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia.	Circulation 20011113
Statin-associated myopathy.	The Medical journal of Australia 20011105
Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia.	FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011101
By the way, doctor...I read about Baycol, the cholesterol-lowering drug being taken off the market because it caused fatal muscle damage. I don't take it, but I do take another statin. Should I be worried?	Harvard health letter 20011101
[Cerivastatin. Which lessons for clinical practice?].	Recenti progressi in medicina 20011101
[We, the Italian physicians, and statins].	Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20011101
Learning from the cerivastatin experience.	Lancet (London, England) 20011027
[Rhabdomyolysis induced by cerivastatin].	Atencion primaria 20011015
[Cerivastatin and gemfibrozil: a dangerous combination].	Atencion primaria 20011015
Regulation of endothelial nitric oxide synthase expression in the vascular wall and in mononuclear cells from hypercholesterolemic rabbits.	Circulation 20011009
Bayer lapse exposes pharma's vulnerability.	Nature biotechnology 20011001
Baycol: take-home messages about medications.	Harvard heart letter : from Harvard Medical School 20011001
Managed care trends in statin usage.	Managed care (Langhorne, Pa.) 20011001
[Useful knowledge and demonstrated competence?].	Medizinische Monatsschrift fur Pharmazeuten 20011001
Substituting for cerivastatin (Baycol).	The Medical letter on drugs and therapeutics 20010917
[Severe rhabdomyolysis associated with cerivastatin and gemfibrozil].	Medicina clinica 20010915
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia.	The American journal of cardiology 20010915
Cerivastatin withdrawn from market.	American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010915
Bayer pulls cerivastatin (Baycol) from market.	CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010904
Rest easy, statin users. Benefits dwarf risks for these cholesterol drugs.	U.S. news & world report 20010903
Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin.	Atherosclerosis 20010901
Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program.	Pharmacotherapy 20010901
[Cholesterin synthase inhibition and atherosclerosis].	Der Internist 20010901
Cerivastatin and gemfibrozil-associated rhabdomyolysis.	The Annals of pharmacotherapy 20010901
Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness.	Clinical therapeutics 20010901
Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia.	Clinical cardiology 20010901
Statin safety.	Nursing standard (Royal College of Nursing (Great Britain) : 1987) 20010901
Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.	Circulation research 20010831
Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction.	Circulation 20010828
Bayer faces potential fine over cholesterol lowering drug.	BMJ (Clinical research ed.) 20010825
[After recall of cerivastatin. How safe are statins in reality? (interview by Dr. Dirk Einecke)].	MMW Fortschritte der Medizin 20010823
Baycol withdrawn from market.	Circulation 20010821
Bayer decides to withdraw cholesterol lowering drug.	BMJ (Clinical research ed.) 20010818
In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor.	FEBS letters 20010817
Cerivastatin-induced rhabdomyolysis in a renal transplant on cyclosporin.	Transplantation 20010815
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.	Carcinogenesis 20010801
Tacrolimus/cerivastatin interaction study in liver transplant recipients.	British journal of clinical pharmacology 20010801
Casebook: jaundice.	The Practitioner 20010801
[Fatal rhabdomyolysis caused by cerivastatin].	Revue medicale de Liege 20010801
Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).	European journal of clinical pharmacology 20010801
Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor.	Circulation 20010731
Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.	Circulation 20010724
Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin.	Clinical cancer research : an official journal of the American Association for Cancer Research 20010701
Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism.	Arteriosclerosis, thrombosis, and vascular biology 20010701
Short-term effects of statin therapy in patients with hyperlipoproteinemia after liver transplantation: results of a randomized cross-over trial.	Journal of hepatology 20010701
Rhabdomyolysis due to cerivastatin monotherapy.	The American journal of medicine 20010615
Normocholesterolaemic dysslipidaemia: is there a role for fibrates?	The Medical journal of Australia 20010604
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles.	Cardiovascular research 20010601
Combination therapy with cerivastatin and gemfibrozil causing rhabdomyolysis: is the interaction predictable?	The American journal of medicine 20010601
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.	The Journal of clinical investigation 20010601
Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition.	American journal of hypertension 20010601
The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.	International journal of clinical pharmacology and therapeutics 20010501
Statin induced myopathy does not show up in MIBI scintigraphy.	Nuclear medicine communications 20010501
Statins and bone formation.	Current pharmaceutical design 20010501
A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.	International journal of clinical practice 20010501
Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect.	FEBS letters 20010427
Rhabdomyolysis after cerivastatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidemia.	AIDS (London, England) 20010413
Safety of statins (hydroxymethyl glutaryl coenzyme a reductase inhibitors): different mechanisms of metabolism and drug transport may have clinical relevance.	Archives of internal medicine 20010409
Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks.	Journal of the American College of Cardiology 20010401
The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor.	British journal of pharmacology 20010401
[Rhabdomyolysis complicated with acute renal insufficiency in a patient treated with gemfibrozil and cerivastatin].	Revista clinica espanola 20010401
Acute rhabdomyolysis associated with cerivastatin therapy.	Archives of internal medicine 20010326
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.	The American journal of cardiology 20010308
Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia.	Circulation 20010306
Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.	Atherosclerosis 20010301
Statin therapy--what now?	Drug and therapeutics bulletin 20010301
[Characteristics of a statine of the most recent generation].	Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20010301
Influence of gender on the pharmacokinetics, safety, and tolerability of cerivastatin in healthy adults.	European journal of clinical pharmacology 20010301
[Ongoing clinical trials by vascular statin, cerivastatin].	Nihon rinsho. Japanese journal of clinical medicine 20010301
[Cerivastatin].	Nihon rinsho. Japanese journal of clinical medicine 20010301
Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.	Journal of the American Society of Nephrology : JASN 20010201
An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro.	Circulation 20010116
Effective use of statins to prevent coronary heart disease.	American family physician 20010115
Statin trials in progress: unanswered questions.	Current atherosclerosis reports 20010101
New statins and new doses of older statins.	Current atherosclerosis reports 20010101
Statins in children: what do we know and what do we need to do?	Current atherosclerosis reports 20010101
The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd.	American journal of kidney diseases : the official journal of the National Kidney Foundation 20010101
Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients.	Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010101
Cerivastatin-induced rhabdomyolisis in a patient with diabetic nephropathy.	American journal of nephrology 20010101
Newer HMG-CoA reductase inhibitor (statin) therapies.	Clinical cardiology 20010101
Severe rhabdomyolysis associated with the cerivastin-gemfibrozil combination therapy: report of a case.	Texas Heart Institute journal 20010101
Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.	Current medical research and opinion 20010101
Synthetic statins: more data on newer lipid-lowering agents.	Current medical research and opinion 20010101
Statin-fibrate combination therapy.	The Annals of pharmacotherapy 20010101
Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia.	The Journal of international medical research 20010101
Clinical-pharmacological strategies to assess drug interaction potential during drug development.	Drug safety 20010101
Changes in bone biochemical markers after high-dose cerivastatin treatment in a woman with osteogenesis imperfecta.	Journal of bone and mineral metabolism 20010101
The evaluation of pharmacologic therapy in humans: a brief summary of the drug evaluation process and guidelines for clinical trials as they related to women.	The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia 20010101
[Rhabdomyolysis and anuric kidney failure induced by the treatment with a gemfibrozil-cerivastatin combination].	Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101
[Cerivastatin and acute kidney failure caused by rhabdomyolysis].	Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101
Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia.	American journal of nephrology 20010101
Withdrawal of cerivastatin from the world market.	Current controlled trials in cardiovascular medicine 20010101
[Massive rhabdomyolysis associated with the use of cerivastatin monotherapy].	Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20010101
Bayer voluntarily withdraws Baycol.	AWHONN lifelines 20010101
A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.	Angiology 20000801
Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy.	The American journal of cardiology 19990401
HMG-CoA reductase inhibitor-induced impotence.	The Annals of pharmacotherapy 19960201
Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the Pravastatin Atherosclerosis Intervention Program.	Circulation 19951101
Currently available hypolipidaemic drugs and future therapeutic developments.	Bailliere's clinical endocrinology and metabolism 19951001
Antihyperlipidaemic agents. Drug interactions of clinical significance.	Drug safety 19941101
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.	The Journal of pharmacology and experimental therapeutics 19910601
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.	Journal of clinical pharmacology 19910101

Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120701

Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

Journal of medicinal chemistry 20120524

Effects of cerivastatin on adrenergic pathways, hypertrophic growth and TGFbeta expression in adult ventricular cardiomyocytes.

European journal of cell biology 20120501

A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrel.

Clinical pharmacology and therapeutics 20120501

The need for translational research on drug-drug interactions.

Clinical pharmacology and therapeutics 20120501

Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules.

Epidemiology (Cambridge, Mass.) 20120301

[Effects of acidification and alkalinization agents on statins-induced muscle toxicity].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20120101

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

PLoS computational biology 20111201

Biological perspectives: update on newer antipsychotic drugs: are they evidence based?

Perspectives in psychiatric care 20111001

Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats.

The Journal of toxicological sciences 20110801

Cerivastatin, genetic variants, and the risk of rhabdomyolysis.

Pharmacogenetics and genomics 20110501

Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by nuclear magnetic resonance-based metabolic profiling.

Analytical biochemistry 20110301

Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.

Drug metabolism and disposition: the biological fate of chemicals 20110201

A predictive ligand-based Bayesian model for human drug-induced liver injury.

Drug metabolism and disposition: the biological fate of chemicals 20101201

Niacin improves small artery vasodilatory function and compliance in statin-treated type 2 diabetic patients.

Diabetes & vascular disease research 20101001

Cerivastatin in vitro metabolism by CYP2C8 variants found in patients experiencing rhabdomyolysis.

Pharmacogenetics and genomics 20101001

Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels.

Journal of neurochemistry 20100901

Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia.

International journal of clinical practice 20100501

Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 20100501

Quantitative phenotyping via deep barcode sequencing.

Genome research 20091001

Cocaine-induced coronary artery dissection.

JACC. Cardiovascular interventions 20091001

Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.

British journal of clinical pharmacology 20090901

[Metabolic rhabdomyolysis during statin therapy].

La Revue de medecine interne 20090801

Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.

British journal of pharmacology 20090801

Statin-induced liver injury involves cross-talk between cholesterol and selenoprotein biosynthetic pathways.

Molecular pharmacology 20090601

Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.

The Journal of pharmacy and pharmacology 20090601

Effect of a combined therapeutic approach of intensive lipid management, omega-3 fatty acid supplementation, and increased serum 25 (OH) vitamin D on coronary calcium scores in asymptomatic adults.

American journal of therapeutics 20090101

Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy.

Xenobiotica; the fate of foreign compounds in biological systems 20090101

The social costs of dangerous products: an empirical investigation.

Cornell journal of law and public policy 20090101

Dermatomyositis induced by drug therapy: a review of case reports.

Journal of the American Academy of Dermatology 20081101

[Anticoagulation in atrial fibrillation].

Hamostaseologie 20081001

Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention.

International journal of cancer 20080901

Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program.

Clinical pharmacology and therapeutics 20080801

Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes.

Drug metabolism and disposition: the biological fate of chemicals 20080701

Effects of cerivastatin withdrawal on statin persistence.

The Annals of pharmacotherapy 20080701

Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells.

International journal of cardiology 20080623

Severe obstructive sleep apnea after cerivastatin therapy: a case report.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 20080615

(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.

Journal of medicinal chemistry 20080508

Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model.

Circulation journal : official journal of the Japanese Circulation Society 20080501

3-Hydroxy-3-methylglutaryl coenzyme A reductase in rainbow trout: effects of fasting and statin drugs on activities and mRNA transcripts.

Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20080401

Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.

Pharmacogenetics and genomics 20080401

Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance.

Surgical infections 20080401

Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.

Pharmacoepidemiology and drug safety 20080301

Metabolic myopathies discovered during investigations of statin myopathy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 20080301

Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

International journal of cardiology 20080227

Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.

Bioorganic & medicinal chemistry letters 20080201

Statins attenuate polymethylmethacrylate-mediated monocyte activation.

Acta orthopaedica 20080201

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

Journal of medicinal chemistry 20080110

Optimal management of combined dyslipidemia: what have we behind statins monotherapy?

Advances in cardiology 20080101

Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.

Internal medicine (Tokyo, Japan) 20080101

Early detection of adverse drug events within population-based health networks: application of sequential testing methods.

Pharmacoepidemiology and drug safety 20071201

Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.

Oncology reports 20071101

A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.

Calcified tissue international 20071101

Physiogenomic association of statin-related myalgia to serotonin receptors.

Muscle & nerve 20070901

Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts.

Clinical and experimental pharmacology & physiology 20070901

Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20070901

Preventive effects of bicarbonate on cerivastatin-induced apoptosis.

International journal of pharmaceutics 20070816

Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.

Bioorganic & medicinal chemistry 20070815

Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.

Toxicology and applied pharmacology 20070815

[Rhabdomyolysis induced by statins].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070810

Effect of cerivastatin on peripheral capillary permeability to albumin and peripheral nerve function in diabetic rats.

Diabetes & metabolism 20070601

The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070601

Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20070401

Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin.

Pharmacological research 20070401

Pharmacogenetics and pharmacogenomics of cholesterol-lowering therapy.

Current opinion in lipidology 20070401

Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages.

The American journal of pathology 20070401

Subcutaneous administration of lactone form of simvastatin stimulates ectopic osteoinduction by rhBMP-2.

Oral diseases 20070301

Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.

Lipids 20070301

Cerivastatin reduces cytokine-induced surface expression of ICAM-1 via increased shedding in human endothelial cells.

Atherosclerosis 20070101

Molecular basis of differences among statins and a comparison with antioxidant vitamins.

The American journal of cardiology 20061204

RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation.

Cell death and differentiation 20061101

Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.

Metabolism: clinical and experimental 20061101

Formulary committees and Medicare Part D.

Journal of the American Geriatrics Society 20061101

Toxicity of statins on rat skeletal muscle mitochondria.

Cellular and molecular life sciences : CMLS 20061001

Single administration of cerivastatin, an HMG-CoA reductase inhibitor, improves the coronary flow velocity reserve: a transthoracic Doppler echocardiography study.

Heart and vessels 20060901

Inhibitory effects of statins on human monocarboxylate transporter 4.

International journal of pharmaceutics 20060706

Differential effects of different statins on endothelin-1 gene expression and endothelial NOS phosphorylation in porcine aortic endothelial cells.

Experimental biology and medicine (Maywood, N.J.) 20060601

Clinical trials in the wake of Vioxx: requiring statistically extreme evidence of benefit to ensure the safety of new drugs.

Circulation 20060509

Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells.

Journal of cardiovascular pharmacology 20060501

Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells.

Atherosclerosis 20060401

Effects of various statins on cytokine-dependent growth and IgE-dependent release of histamine in human mast cells.

Allergy 20060301

Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.

Journal of the American Geriatrics Society 20060301

'Anti-inflammatory' drugs and their effects on type 2 diabetes.

Diabetes technology & therapeutics 20060201

Statins and osteoporosis: new role for old drugs.

The Journal of pharmacy and pharmacology 20060101

Cerivastatin and hypercholesterolemia reduce apoptosis of cardiomyocytes in guinea pig papillary muscle subjected to hypoxia/reoxygenation.

Pharmacological reports : PR 20060101

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

Cardiovascular diabetology 20060101

Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway.

Cardiovascular research 20051201

Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform.

Cardiovascular research 20051201

Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity.

Toxicological sciences : an official journal of the Society of Toxicology 20051201

Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.

Diabetic medicine : a journal of the British Diabetic Association 20051201

Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.

Diabetic medicine : a journal of the British Diabetic Association 20051201

The effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.

The Journal of surgical research 20051101

Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.

The Journal of pharmacy and pharmacology 20051101

Differential associations of statin and fibrate treatment with carotid arterial remodeling.

American journal of hypertension 20051101

Statin toxicity: a situation that mimics viral hepatitis.

International journal of clinical pharmacology and therapeutics 20051101

[Drug combinations: statins and fibrates].

Arquivos brasileiros de cardiologia 20051001

Evaluation of apoptosis and necrosis induced by statins using fluorescence-enhanced flow cytometry.

Journal of pharmaceutical and biomedical analysis 20050915

Binding thermodynamics of statins to HMG-CoA reductase.

Biochemistry 20050906

Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.

The Journal of pharmacology and experimental therapeutics 20050901

Differences between statins on clinical endpoints: a population-based cohort study.

Current medical research and opinion 20050901

Using Crestor--and all statins--safely. Some simple steps can help minimize or avoid muscle problems from these cholesterol-lowering drugs.

Harvard heart letter : from Harvard Medical School 20050901

New light on statin side effects. What recent research on the cholesterol drugs means to you.

Heart advisor 20050801

[High doses statins administration causing rhabdomyolysis: case report].

Arquivos brasileiros de endocrinologia e metabologia 20050801

Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor.

Drug metabolism and disposition: the biological fate of chemicals 20050701

Combination therapy with cerivastatin and nifedipine improves endothelial dysfunction after balloon injury in porcine coronary arteries.

Journal of cardiovascular pharmacology 20050701

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells.

Pharmacogenetics and genomics 20050701

The effect of statin therapy on endothelial function in type 2 diabetes without manifest cardiovascular disease.

Diabetes care 20050701

No effect of statin therapy on silent myocardial ischemia in patients with type 2 diabetes without manifest cardiovascular disease.

Diabetes care 20050701

In vivo and in vitro effects of statins on lymphocytes in patients with Hashimoto's thyroiditis.

European journal of endocrinology 20050701

The issue of statin safety: where do we stand?

Circulation 20050614

The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis.

Circulation 20050614

Prediction of genotoxicity of chemical compounds by statistical learning methods.

Chemical research in toxicology 20050601

Intense cholesterol lowering therapy with a HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type-2-diabetes--a multicenter, randomised, double-blind, three-arm placebo-controlled clinical trial.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20050601

Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men.

Diabetes, obesity & metabolism 20050501

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardio-vascular disease: response to Beishuizen et al.

Diabetes care 20050501

More on: fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells.

Journal of thrombosis and haemostasis : JTH 20050501

Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.

Journal of clinical pharmacy and therapeutics 20050401

Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients.

American heart journal 20050301

Influence of coenzyme Q(10) and cerivastatin on the flow-mediated vasodilation of the brachial artery: results of the ENDOTACT study.

International journal of cardiology 20050227

Statins suppress oxidized low density lipoprotein-induced macrophage proliferation by inactivation of the small G protein-p38 MAPK pathway.

The Journal of biological chemistry 20050225

Relaxant effects of pravastatin, atorvastatin and cerivastatin on isolated rat aortic rings.

Life sciences 20050225

Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).

Bioorganic & medicinal chemistry letters 20050215

Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo.

Molecular therapy : the journal of the American Society of Gene Therapy 20050201

Improvement of arterial stiffness by the antioxidant and anti-inflammatory effects of short-term statin therapy in patients with hypercholesterolemia.

Heart and vessels 20050201

Effects of switching pravastatin to cerivastatin on C-reactive protein, butyrylcholinesterase, and lipids.

Current medical research and opinion 20050201

Differential effect of cerivastatin and L-arginine on the vascular function of human radial and left internal thoracic arteries.

Journal of cardiac surgery 20050101

Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity.

Toxicologic pathology 20050101

Analysis of the global RNA expression profiles of skeletal muscle cells treated with statins.

Journal of atherosclerosis and thrombosis 20050101

Mechanisms of calcium release from the sarcoplasmic reticulum in skeletal muscle.

Advances in experimental medicine and biology 20050101

[Severe muscle disorders associated with statins: analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin].

Therapie 20050101

[Comparison of reports from patients and health professionals: statins and muscle disorders].

Therapie 20050101

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

Acute effect of cerivastatin on cardiac regional ischemia in a rat model mimicking off-pump coronary surgery.

Journal of cardiac surgery 20050101

[Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].

Kokuritsu Iyakuhin Shokuhin Eisei Kenkyujo hokoku = Bulletin of National Institute of Health Sciences 20050101

In vitro and in vivo correlation of the inhibitory effect of cyclosporin A on the transporter-mediated hepatic uptake of cerivastatin in rats.

Drug metabolism and disposition: the biological fate of chemicals 20041201

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease.

Diabetes care 20041201

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.

JAMA 20041201

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.

JAMA 20041201

Bayer's response to 'potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis'.

JAMA 20041201

The effect of statins on angiotensin II-induced hemodynamic changes in young, mildly hypercholesterolemic men.

American journal of hypertension 20041201

Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.

Journal of cellular biochemistry 20041115

Simple, sensitive and rapid LC-MS/MS method for the quantitation of cerivastatin in human plasma--application to pharmacokinetic studies.

Journal of pharmaceutical and biomedical analysis 20041115

Rosuvastatin safety: lessons from the FDA review and post-approval surveillance.

Expert opinion on drug safety 20041101

Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.

Thrombosis and haemostasis 20041101

The effect of cerivastatin therapy on vascular responses to endothelin antagonists in humans.

Journal of cardiovascular pharmacology 20041101

Optimal windows of statin use for immediate infarct limitation: 5'-nucleotidase as another downstream molecule of phosphatidylinositol 3-kinase.

Circulation 20041012

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.

The Journal of pharmacology and experimental therapeutics 20041001

Simvastatin and survival in sepsis.

Circulation 20040921

Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms.

European journal of pharmacology 20040913

Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathways.

The Journal of biological chemistry 20040910

Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.

Applied immunohistochemistry & molecular morphology : AIMM 20040901

Bayer to settle lawsuits over Baycol.

Health news (Waltham, Mass.) 20040901

Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse.

Circulation 20040831

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.

Arteriosclerosis, thrombosis, and vascular biology 20040801

The cerivastatin withdrawal crisis: a 'post-mortem' analysis.

Health policy (Amsterdam, Netherlands) 20040801

Combined antihypertensive and lipid-lowering treatment.

Current hypertension reports 20040801

Different effects of pravastatin and cerivastatin on the media of the carotid arteries as assessed by integrated backscatter ultrasound.

Circulation journal : official journal of the Japanese Circulation Society 20040801

Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice.

Naunyn-Schmiedeberg's archives of pharmacology 20040801

Effect of cerivastatin on endothelial dysfunction and aortic CD36 expression in diabetic hyperlipidemic rats.

Hypertension research : official journal of the Japanese Society of Hypertension 20040801

Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism.

Circulation 20040727

Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis.

Arteriosclerosis, thrombosis, and vascular biology 20040701

Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis.

Hypertension (Dallas, Tex. : 1979) 20040601

Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.

International journal of oncology 20040501

Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040501

Cerivastatin activates endothelial calcium-activated potassium channels and thereby modulates endothelial nitric oxide production and cell proliferation.

Journal of the American Society of Nephrology : JASN 20040401

Cerivastatin-induced polymyalgia rheumatica-like illness.

Clinical rheumatology 20040401

[Polymyositis induced or associated with lipid-lowering drugs: five cases].

La Revue de medecine interne 20040401

Time course differences for statin-induced pleiotropic effects in hypercholesterolemic patients.

International journal of cardiology 20040301

Site-specific effects of cerivastatin on bone in male Sprague-Dawley rats.

Bone 20040301

Cerivastatin inhibits proliferation of interleukin-1 beta-induced rat mesangial cells by enhanced formation of nitric oxide.

European journal of pharmacology 20040206

Early detection of drug interactions utilizing a computerized drug prescription handling system-focus on cerivastatin-gemfibrozil.

European journal of clinical pharmacology 20040201

Beneficial effects of statins in patients with non-ischemic heart failure.

Zeitschrift fur Kardiologie 20040201

Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.

Drug safety 20040101

Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats.

Toxicology and applied pharmacology 20040101

Cerivastatin-induced apoptosis of human aortic smooth muscle cells through partial inhibition of basal activation of extracellular signal-regulated kinases.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20040101

The influence of statins on the free intracellular calcium concentration in human umbilical vein endothelial cells.

BMC cardiovascular disorders 20040101

Cerivastatin does not prevent oxidative injury of human aortic endothelial cells.

Texas Heart Institute journal 20040101

A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin.

Journal of human genetics 20040101

Differential in vitro response of the human radial artery versus left internal thoracic artery to cerivastatin: implications to bypass grafting.

The Annals of thoracic surgery 20031201

Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development.

Circulation research 20031114

HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.

Basic research in cardiology 20031101

Determination of the pharmacokinetics of cerivastatin when administered in combination with sirolimus and cyclosporin A in patients with kidney transplant, and review of the relevant literature.

International journal of clinical pharmacology and therapeutics 20031101

Ca2+-releasing effect of cerivastatin on the sarcoplasmic reticulum of mouse and rat skeletal muscle fibers.

Journal of pharmacological sciences 20031101

Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine.

The Journal of biological chemistry 20031031

Direct anti-inflammatory mechanisms contribute to attenuation of experimental allograft arteriosclerosis by statins.

Circulation 20031028

Withdrawal of cerivastatin induces monocyte chemoattractant protein 1 and tissue factor expression in cultured vascular smooth muscle cells.

Arteriosclerosis, thrombosis, and vascular biology 20031001

Skeletal reconstruction by vascularized allogenic bone transplantation: effects of statin in rats.

Transplantation 20030915

Cardiac magnetic resonance imaging in small animal models of human heart failure.

Medical image analysis 20030901

Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure.

International journal of cardiology 20030901

Platelet hyperactivity after statin treatment discontinuation.

Thrombosis and haemostasis 20030901

The HMG-CoA reductase inhibitor cerivastatin enhances the nitric oxide bioavailability of the endothelium.

Journal of cardiovascular pharmacology 20030901

Second hand smoke stimulates tumor angiogenesis and growth.

Cancer cell 20030901

3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.

Journal of molecular and cellular cardiology 20030801

Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.

Clinical pharmacology and therapeutics 20030801

Tacrolimus and cerivastatin pharmacokinetics and adverse effects after single and multiple dosing with cerivastatin in renal transplant recipients.

British journal of clinical pharmacology 20030801

HMG-CoA reductase inhibitor cerivastatin inhibits interleukin-6 expression and secretion in human adipocytes.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030801

Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.

Circulation 20030722

Intestinal pseudobstruction as presenting event of fatal cerivastatin-induced myopathy.

Journal of neurology 20030701

Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.

Molecular and cellular biochemistry 20030701

Of cancer and cholesterol: studies elucidate anticancer mechanisms of statins.

Journal of the National Cancer Institute 20030618

Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.

The American journal of cardiology 20030615

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model.

Diabetologia 20030601

Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.

Arteriosclerosis, thrombosis, and vascular biology 20030501

Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era.

Expert opinion on drug safety 20030501

Vascular smooth muscle cell activation by C-reactive protein.

Cardiovascular research 20030401

The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction.

Molecular and cellular biochemistry 20030401

Safety and statin therapy: reconsidering the risks and benefits.

Archives of internal medicine 20030324

Bayer is forced to release documents over withdrawal of cerivastatin.

BMJ (Clinical research ed.) 20030308

How a statin might destroy a drug company.

Lancet (London, England) 20030308

Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.

Cellular signalling 20030301

Statins and myotoxicity.

Current atherosclerosis reports 20030301

Effects of cerivastatin on human arterial smooth muscle cell growth and extracellular matrix expression at varying glucose and low-density lipoprotein levels.

Journal of cardiovascular pharmacology 20030301

Insights in the molecular mechanisms of the anti-angiogenic effect of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Thrombosis and haemostasis 20030301

Statins and myotoxicity.

Trends in pharmacological sciences 20030301

Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression.

Biochimica et biophysica acta 20030217

HMG-CoA reductase inhibitor enhances inducible nitric oxide synthase expression in rat vascular smooth muscle cells; involvement of the Rho/Rho kinase pathway.

Atherosclerosis 20030201

Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.

The Journal of pharmacology and experimental therapeutics 20030201

HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20030201

HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells.

Arteriosclerosis, thrombosis, and vascular biology 20030201

[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors].

Der Nervenarzt 20030201

[Cerivastatin and the PRINCESS study: reflexions after 1 year].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20030201

Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function).

Circulation 20030128

Myoglobinuria and COX deficiency in a patient taking cerivastatin and gemfibrozil.

Neurology 20030114

Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.

American journal of nephrology 20030101

Effects of cerivastatin on vascularized allogenic bone transplantation in rats treated with cyclosporine A.

Calcified tissue international 20030101

Extracellular signal-regulated kinase inhibition by statins inhibits neutrophil activation by ANCA.

Kidney international 20030101

The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20030101

HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.

Stroke 20030101

Cerivastatin and atorvastatin inhibit IL-3-dependent differentiation and IgE-mediated histamine release in human basophils and downmodulate expression of the basophil-activation antigen CD203c/E-NPP3.

Journal of leukocyte biology 20030101

Issues that led to the withdrawal of cerivastatin.

Current atherosclerosis reports 20030101

Cerivastatin: a cellular and molecular drug for the future?

Cellular and molecular life sciences : CMLS 20030101

[Information regarding adverse drug effects and treatment indications ('package inserts') exemplified by cervistatin (Lipobay)].

Wiener medizinische Wochenschrift (1946) 20030101

Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells.

Journal of atherosclerosis and thrombosis 20030101

[Adverse effects of statins].

Therapie 20030101

[Clinico-pharmacologic explanation models of cerivastatin associated rhabdomyolysis].

Wiener medizinische Wochenschrift (1946) 20030101

Cerivastatin ameliorates high insulin-enhanced neutrophil-endothelial cell adhesion and endothelial intercellular adhesion molecule-1 expression by inhibiting mitogen-activated protein kinase activation.

Journal of diabetes and its complications 20030101

Effectiveness of statin-gemfibrozil combination therapy in patients with mixed hyperlipidemia: experience of a community lipid clinic and safety review from the literature.

Preventive cardiology 20030101

Interaction between fibrates and statins--metabolic interactions with gemfibrozil.

Drug metabolism and drug interactions 20030101

Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials.

BMC family practice 20030101

Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.

Circulation 20021203

Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201

Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.

Drug metabolism and disposition: the biological fate of chemicals 20021201

Statin inhibits leukocyte-endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina.

Archives of ophthalmology (Chicago, Ill. : 1960) 20021201

Limited adherence to safety instructions in drug leaflets.

British journal of clinical pharmacology 20021201

Gemfibrozil greatly increases plasma concentrations of cerivastatin.

Clinical pharmacology and therapeutics 20021201

Cerivastatin, a HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promoter activity.

Japanese journal of pharmacology 20021201

High rates of adverse effects and patient unawareness of withdrawn lipid-lowering drug combination in a public hospital clinic.

Pharmacoepidemiology and drug safety 20021201

Cerivastatin potentiates nitric oxide release and enos expression through inhibition of isoprenoids synthesis.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20021201

Side effects of statins--prevalence, relevance, consequences.

Wiener klinische Wochenschrift 20021130

Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).

Cancer letters 20021128

Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines.

FEBS letters 20021120

Impact of hydroxymethylglutaryl coenzyme a reductase inhibition on left ventricular remodeling after myocardial infarction: an experimental serial cardiac magnetic resonance imaging study.

Journal of the American College of Cardiology 20021106

Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells.

Atherosclerosis 20021101

Dysbetalipoproteinaemia--clinical and pathophysiological features.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20021101

Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin.

European journal of pharmacology 20021025

TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS.

Cardiovascular research 20021001

Anti-inflammatory effect of cerivastatin in vascular injury independent of serum cholesterol and blood pressure lowering effects in mouse model.

Chinese journal of traumatology = Zhonghua chuang shang za zhi 20021001

Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia.

The American journal of cardiology 20021001

Rhabdomyolysis and cerivastatin: was it a problem of dose?

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20021001

Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects.

British journal of clinical pharmacology 20021001

Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.

International journal of hematology 20021001

[Surrogate end points as a clinical and public health problem. The cerivastatin case].

Medicina clinica 20020907

Postischemic acute renal failure is reduced by short-term statin treatment in a rat model.

Journal of the American Society of Nephrology : JASN 20020901

Cerivastatin and gemfibrozil-induced cardiac rhabdomyolysis.

The American journal of forensic medicine and pathology 20020901

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Stroke 20020901

Controversy surrounding the safety of cerivastatin.

Expert opinion on drug safety 20020901

Influence of lipid-lowering therapy on the progression of coronary artery calcification: a prospective evaluation.

Circulation 20020827

ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins.

Circulation 20020820

Contacting patients of a Pakistani hospital about a drug recall.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020815

ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Journal of the American College of Cardiology 20020807

Mechanisms of inhibitory effects of cerivastatin on rat vascular smooth muscle cell growth.

Journal of cardiovascular pharmacology 20020801

Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.

Diabetes 20020801

The use of statins after solid organ transplantation.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020801

Withdrawal of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors elicits oxidative stress and induces endothelial dysfunction in mice.

Circulation research 20020726

Severe rhabdomyolysis related to cerivastatin without gemfibrozil.

Annals of internal medicine 20020702

Rho/Rho-kinase is involved in the synthesis of tissue factor in human monocytes.

Atherosclerosis 20020701

Rhabdomyolysis-related renal tubular damage studied by proton nuclear magnetic resonance spectroscopy of urine.

Clinical chemistry 20020701

A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.

Journal of vascular surgery 20020701

Effects of cerivastatin and parathyroid hormone on the lumbar vertebra of aging male Sprague-Dawley rats.

Bone 20020701

Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

Pharmacology & therapeutics 20020701

Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein peroxidation with antioxidant probucol.

Bulletin of experimental biology and medicine 20020701

Inhibition of Rho/Rho-kinase signaling downregulates plasminogen activator inhibitor-1 synthesis in cultured human monocytes.

Biochimica et biophysica acta 20020612

Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells.

Cardiovascular research 20020601

Cerivastatin and the dissemination of adverse event information.

The Annals of pharmacotherapy 20020601

Rhabdomyolysis from high-dose cerivastatin therapy.

The Annals of pharmacotherapy 20020601

Implementation of a therapeutic-interchange clinic for HMG-CoA reductase inhibitors.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020601

Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.

Pharmacotherapy 20020601

Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism.

Arteriosclerosis, thrombosis, and vascular biology 20020601

Rho-GTPase-dependent platelet-neutrophil interaction affected by HMG-CoA reductase inhibition with altered adenosine nucleotide release and function.

Arteriosclerosis, thrombosis, and vascular biology 20020601

Effects of cerivastatin on vascular function of human radial and left internal thoracic arteries.

The Annals of thoracic surgery 20020601

A randomized, double-blind comparison of cerivastatin and lovastatin for treatment of primary hypercholesterolemia.

Zhonghua yi xue za zhi = Chinese medical journal; Free China ed 20020601

[Rhabdomyolisis associated with cerivastatin and cyclosporine combination therapy].

Medicina clinica 20020518

[Acute cholestatic hepatitis induced by cerivastatin].

Medicina clinica 20020518

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

Drug metabolism and disposition: the biological fate of chemicals 20020501

Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20020501

Statins and the assessment of endothelial function.

Journal of internal medicine 20020501

Issues concerning the monitoring of statin therapy in hypercholesterolemic subjects with high plasma lipoprotein(a) levels.

Lipids 20020501

Statins and muscles: what price glory?

Joint, bone, spine : revue du rhumatisme 20020501

Interaction between blood pressure, lipoproteins, angiotensin, and vascular disease.

Current hypertension reports 20020401

HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20020401

Severe rhabdomyolysis and cerivastatin-gemfibrozil combination therapy.

The Annals of pharmacotherapy 20020401

Cerivastatin-induced rhabdomyolysis: 11 case reports.

Pharmacotherapy 20020401

Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models.

Arteriosclerosis, thrombosis, and vascular biology 20020401

[Myotoxicity and rhabdomyolisis due to statins].

Nederlands tijdschrift voor geneeskunde 20020302

Statin stories.

Diabetes, obesity & metabolism 20020301

Rhabdomyolysis associated with cerivastatin plus gemfibrozil combined regimen.

The British journal of general practice : the journal of the Royal College of General Practitioners 20020301

HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.

Cardiovascular drugs and therapy 20020301

Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin.

Circulation 20020226

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.

The American journal of cardiology 20020215

Cerivastatin and reports of fatal rhabdomyolysis.

The New England journal of medicine 20020214

Statins have biphasic effects on angiogenesis.

Circulation 20020212

Why some patients respond poorly to statins and how this might be remedied.

European heart journal 20020201

Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case--a modern Pandora's box.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20020201

Risperidone and severe cerivastatin-induced rhabdomyolysis.

Journal of internal medicine 20020201

Apolipoprotein E alleles, dyslipemia and kidney transplantation.

Transplantation proceedings 20020201

Effects of cerivastatin in dyslipemia and other cardiovascular risk factors after renal transplantation.

Transplantation proceedings 20020201

Cholesterol drugs: very safe and highly beneficial.

The Johns Hopkins medical letter health after 50 20020201

Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days.

Circulation 20020129

Cerivastatin and endothelial function in elderly patients with diabetes mellitus.

Circulation 20020129

Bayer faces Swiss criminal probe over cerivastatin.

BMJ (Clinical research ed.) 20020119

Kinetic properties and inhibition of Trypanosoma cruzi 3-hydroxy-3-methylglutaryl CoA reductase.

FEBS letters 20020116

Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

Biochemical and biophysical research communications 20020111

Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.

Journal of internal medicine 20020101

[Unexpected consequences of an expected adverse effect of cerivastatine].

La Revue de medecine interne 20020101

[Attitude to and marketing of cerivastatin].

Acta medica Austriaca 20020101

[Rhabdomyolysis, acute renal failure and use of cerivastatin combined with gemfibrozil. New evidence].

Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20020101

Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat.

Polish journal of pharmacology 20020101

[Myopathy due to statins, a dose-dependent effect, and of what kind?].

Atencion primaria 20020101

Cerivastatin induces rhabdomyolysis and acute renal failure.

Nephron 20020101

HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.

Internal medicine journal 20020101

Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.

WMJ : official publication of the State Medical Society of Wisconsin 20020101

A multidisciplinary program for achieving lipid goals in chronic hemodialysis patients.

BMC nephrology 20020101

[Myopathy with rhabdomyolysis as an adverse effect of simultaneous treatment with cerivastatin and gemfibrozil].

Lijecnicki vjesnik 20020101

HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.

Biochemical and biophysical research communications 20011214

[Myotoxicity and rhabdomyolisis due to statins].

Nederlands tijdschrift voor geneeskunde 20011208

Massive rhabdomyolysis and life threatening hyperkalaemia in a patient with the combination of cerivastatin and gemfibrozil.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20011201

Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells.

Arteriosclerosis, thrombosis, and vascular biology 20011201

145599-86-6 | 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)-

Product Description

Properties

Literature

Related Products

Featured Products